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Abstract
Rationale Recent studies have shown that cannabis may dis-
rupt glutamate (Glu) signaling depressing Glu tone in frequent
users. Current evidence have also consistently reported lower
Glu-levels in various brain regions, particularly in the medial
prefrontal cortex (mPFC) of chronic schizophrenia patients,
while findings in early psychosis (EP) are not conclusive.
Since cannabis may alter Glu synaptic plasticity and its use
is a known risk factor for psychosis, studies focusing on Glu
signaling in EP with or without a concomitant cannabis-usage
seem crucial.
Objective We investigate the effect of cannabis use on pre-
frontal Glu-levels in EP users vs. both EP non-users and
healthy controls (HC).
Methods Magnetic resonance spectroscopy was used to mea-
sure [GlumPFC] of 35 EP subjects (18 of whom were cannabis
users) and 33 HC. For correlative analysis, neuropsychologi-
cal performances were scored by the MATRICS-consensus
cognitive battery.
Results [GlumPFC] was lower in EP users comparing to both
HC and EP non-users (p < 0.001 and p = 0.01, respectively),
while no differences were observed between EP non-users and
HC. A greater [GlumPFC]-decline with age was observed in EP
users (r = −.46; p = 0.04), but not in EP non-users or HC.
Among neuropsychological outcomes, working memory was
the only domain that differentiates patients depending on their
cannabis use, with users having poorer performances.
Conclusions Cannabis use is associated with reduced prefron-
tal [GlumPFC] and with a stronger Glu-levels decline with age.
Glutamatergic abnormalities might influence the cognitive im-
pairment observed in users and have some relevance for the
progression of the disease.
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Introduction
Δ9-tetrahydrocannabinol (THC), the primary psychoactive
cannabinoid present within cannabis, exerts its effect by bind-
ing the cannabinoid receptors type 1 (CB1R) that are widely
distributed in the brain. Consequently, the long-term use of
cannabis might cause alterations in both morphology and
function of brain regions rich in CB1R (i.e., prefrontal cortex,
hippocampus, amygdala, cerebellum), but so far findings are
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still controversial (Lorenzetti et al. 2015). If the impact of
cannabis use on brain structure is largely investigated, still
little is known about the effect of cannabis on brain tissue’s
neurochemical profiles. Proton magnetic resonance spectros-
copy (1H MRS), is a non-invasive measurement technique
that enables the in vivo detection of a wide range of
neurometabolites including neurotransmitters. Among them,
glutamate (Glu) could be considered as a promising candidate
to capture the effects of cannabis on the brain (for a review see
Colizzi et al. 2016). There is indeed a large body of evidence
accumulated from animal studies demonstrating that in vivo
administration of THC affects the release of Glu in the pre-
frontal cortex (PFC), and that this process is mediated by
CB1R (Pistis et al. 2001). Specifically, the administration of
THC depresses endocannabinoid-mediated glutamatergic
synaptic transmission, affecting the release, the enzyme activ-
ity, and the expression of both Glu-receptors and transporters
(Colizzi et al. 2016). Also, prolonged THC exposure affects
Glu synaptic plasticity by a functional tolerance mechanism,
reducing the ability of CB1R-agonists to inhibit Glu synaptic
transmission (Mato et al. 2005).
The application of MRS to investigate the effect of canna-
bis in humans, although limited by the paucity of studies,
tends to replicate findings of animal models. To the best of
our knowledge, only four authors examined in vivo Glu-
related metabolites levels in cannabis users, while only one
prior study focused on a population of schizophrenia patients
with a concomitant cannabis usage. Lower levels of Glu, N-
acetylaspartate (NAA), and myo-inositol (mIns) were ob-
served in regular cannabis users without a psychiatric disorder
compared to control subjects, in regions known to be associ-
ated with substance use: including the dorsal striatum in 27
subjects (Muetzel et al. 2013), the anterior cingulate cortices
in 17 and 13 cannabis users, respectively (Prescot et al. 2011,
2013), and the basal ganglia and thalamus in 24 individuals
without psychosis (Chang et al. 2006). The only study focus-
ing on patients with schizophrenia found a specific effect of
substance use on reducing levels of Glu plus Glutamine (Gln)
(Bernier et al. 2016).
The impact of THC on Glu-signaling is of considerable
interest as it offers a possible key to unravel the neurobiolog-
ical substrate of the clinical phenotype of cannabis-associated
psychosis. Supporting an integrated hypothesis, several lines
of evidences point indeed to there being an hypo-functioning
Glu neurotransmission leading to the presynaptic dopamine
dysfunction consistently reported in schizophrenia, which
may provide the best explanation of all the clinical aspects
of this heterogeneous and complex disorder (Howes et al.
2015). Furthermore, recent studies have shown decreased
Glu levels in schizophrenia patients when compared to
healthy individuals, particularly in medial frontal region
(Marsman et al. 2013). Moreover, chronicity in schizophrenia
was found to be related to decreased prefrontal Glu (Natsubori
et al. 2014), Glx (Glu + Gln) and NAA levels (Liemburg et al.
2016); with evidence for a time-depending role for Glu
(Merritt et al. 2016), whereas findings in early psychosis
(EP) are still controversial (for a review see Treen et al.
2016). While the studies presented above provide evidence
that THC leads to glutamatergic dysfunction, they do not un-
equivocally identify the specific brain circuits or regions in-
volved. The PFC has been suggested, among others, as a
potential target-site as glutamatergic projections to the mid-
brain regulate midbrain dopamine neurons (Howes et al.
2015). Furthermore, the prefrontal cortical and subcortical
changes in metabolism occurring within cannabis users are
thought to disturb prefrontal cortical maturation, which could
ultimately give rise to neurobiological impairments
(Zamberletti et al. 2014; Rubino et al. 2015).
THC seems therefore to have the potential to disrupt the
normal interplay between neurotransmitters in PFC, particu-
larly Glu, and may bear relevance in understanding THC-
associated cognitive and clinical dimensions. The aim of the
present study was to employ 1H MRS for investigating Glu
levels in the mPFC of EP cannabis users compared with their
non-using counterpart and normative healthy controls.
Based on this background we hypothesized:
(i) a reduced glutamate level in EP subjects who used can-
nabis compared to EP non-users and healthy controls,
respectively
(ii) the absence of a difference between EP non-users and
HC in terms of [GlumPFC]
(iii) a correlation between level of cognitive deficits in EP
users and pre-frontal glutamatergic dysfunction
Method
Subjects
Thirty-five EP subjects, of whom 18 were currently cannabis
users, were recruited from the Treatment and Early
Intervention in Psychosis Program (TIPP), of the University
Hospital in Lausanne (Baumann et al. 2013). The TIPP is a
specialized 3-year early psychosis programme. Entry criteria
to the program are (i) age between 18 and 35 years; (ii) resi-
dence in the catchment area (Lausanne and surrounding); (iii)
meeting threshold criteria for psychosis, as defined by the
‘Psychosis threshold’ subscale of the Comprehensive
Assessment of At Risk Mental States (CAARMS) (Yung
et al. 2005); and (iv) not more than 6 months of treatment with
antipsychotic medication for the psychotic disorder. The
CAARMS is a clinical tool to assess if subjects meet criteria
for being at ultra-high risk for onset of first psychotic disorder.
The BPsychosis threshold^ subscale allows assessing if a
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subject fulfills criteria for a Bfull blown^ psychotic episode.
The diagnostic assessment for TIPP patients is the result of an
expert consensus and is based on the following elements:
(Andreasen et al. 2010) diagnosis reported by treating psychi-
atrist in all medical documents and at the end of any hospital-
ization; (Arseneault et al. 2002) longitudinal assessment by
clinical case managers over the 3 years of treatment. The con-
sensus diagnosis procedure realized by a senior psychiatrist
and the senior psychologist who is in charge of scale-based
assessment over the treatment period. They both review the
entire file once after 18months and again after 36months or at
the end of treatment and conduct a diagnostic process based
on DSM-IV criteria (APA 1994) discussing any unclear issue
with the clinical case manager. In this paper, only the final
diagnosis, defined at the end of TIPP treatment period, is
considered. Thirty-three healthy controls matched on gender,
age, and handedness were recruited from similar geographic
and socio-demographic areas and assessed by the Diagnostic
Interview for Genetic Studies (Preisig et al. 1999). Major
mood, psychotic, or substance-use disorder and having a
first-degree relative with a psychotic disorder were exclusion
criteria for controls. Neurological disorders and severe head
trauma were exclusion criteria for all subjects. 31 of the 35
patients were on antipsychotic medication at the time of this
study, with an average medication of 329.3 ± 212.1 mg chlor-
promazine equivalent dose (CPZ) (Andreasen et al. 2010)
(Table 1). Informed written consent in accordance with our
institutional guidelines (protocol approved by the Ethic
Committee of Lausanne University) was obtained for all the
subjects.
Assessment of cannabis use
A detailed history of illicit drug use (cannabis, stimulants and
any other recreational drug) was taken using a specially de-
signed questionnaire (the TIPP Initial Assessment Tool:
TIAT). This allows a detailed assessment of lifetime patterns
of cannabis use, including frequency and duration of use
and age at first use. The measures of exposure to cannabis
use included in the analyses were (a) current cannabis use (is
the subject currently using cannabis: no = 0; yes = 1); (b)
lifetime frequency of cannabis use [the frequency that charac-
terized the subject’s most consistent pattern of use: at week-
ends or less frequently (occasional) = 0; every day (daily) = 1];
and (c) age at first use (the age when the subject started to use
cannabis regularly: prior to age 15 years = 0; above age
15 years = 1). This cut-off was based on previous studies
showing an increased risk of mental health disorders in users
of cannabis before the age of 15 (Arseneault et al. 2002;
Fontes et al. 2011). On the basis of this data, EP patients were
dichotomised between (a) regular cannabis users and (b) oc-
casional users.
Neuropsychological assessment
Neuropsychological assessment was made according to the
BMeasurement and Treatment Research to improve
Cognition in Schizophrenia^ (MATRICS Consensus
Cognitive Battery), excluding the Mayer-Salovey-Caruso
Emotional Intelligence Test (MSCEIT), which does not
Btranslate^ well into French as an index of social cognition.
This includes six factors (speed of processing, sustained atten-
tion/vigilance, working memory, verbal and visual learning,
reasoning and problem-solving) (Nuechterlein et al. 2008), on
the basis of the following subtests: Trail Making Test (TMT):
part A; Symbol Coding—Brief Assessment of Cognition in
Schizophrenia (BACS): symbol coding; Verbal (category)
Fluency: animal naming; Continuous Performance Test-
Identical Pairs (CPT-IP); Spatial Span—Wechsler Memory
Scale-Third Edition (WMS-III): spatial span; Scale-Third
Edition; Letter-Number Span (LNS); Hopkins Verbal
Learning Test-Revised (HVLT-R); Brief Visuospatial
Memory Test-Revised (BVMT-R); Mazes – Neuropsy-
chological Assessment Battery (NAB): mazes. Median time
from admission to the TIPP programme and toMRS scan was
375.03 ± 331.3 days. Median time from MRS scan to clinical
assessment was 20.6 ± 6 days.
Table 1 Subjects characteristics
EP users (N = 18)
Mean ± SD
EP non-users (N = 17)
Mean ± SD
HC (N = 33)
Mean ± SD
Statistics
Age, years 27.1 (6.2) 24.8 (6.1) 25.3 (4.5) F(2.67) = 1.1 p = 0.3
Gender, M/F 13/5 9/8 16/17 χ2 = 4.1 p = 0.1
Handedness R/L/A 15/2/1 14/2/1 26/7/0 χ2 = 5 p = 0.7
Duration of illness, days 774.8 (772.9) 867.3 (754.4) – t = − .38 p = 0.7
Medication dose, mga 320.9 (336.2) 331.3 (227.1) – t = − .1 p = 0.9
Patterns of use (every day users, %) 8 (44.4) – –
EP early psychosis, HC healthy controls
a Four patients were not on antipsychotics at time of scanning
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1H magnetic resonance spectroscopy
1H MRS measurements were performed on the 3T MR scan-
ner (Magnetom TimTrio, Siemens Healthcare, Erlangen,
Germany) with a transverse electromagnetic (TEM 3000)
head coil (MR Instruments, Inc). The magnetic field homoge-
neity was optimized by adjusting first- and second-order
shims using FAST(EST)MAP (Gruetter 1993; Gruetter and
Tkac 2000).
In vivo 1H MR spectra were acquired from the medial
prefrontal cortex (mPFC; Fig. 1a) using a short-TE spin-echo
full-intensity acquired localized single voxel spectroscopy
technique (SPECIAL) (Mekle et al. 2009; Mlynarik et al.
2006). Outer volume suppression (OVS) (Tkac et al. 2001)
and water suppression with variable-pulse power and opti-
mized relaxation delays (VAPOR) (Tkac et al. 1999) were
applied prior to the SPECIAL localization sequence. The fol-
lowing scan parameters were used: volume of interest
(VOI = 20 × 20 × 25 mm3), echo time/repetition time (TE/
TR) = 6/4000 ms, acquisition bandwidth = 2 kHz, number of
averages = 148, vector size = 2.
Spectral quantification
To obtain [GlumPFC] water suppressed in vivo,
1H MR
spec t r a we re ana lyzed by LCMode l (S t ephen
Provencher, Inc) using a basis-set consisting of 20 simu-
lated individual metabolite spectra: alanine (Ala),
aspartate (Asp), phosphocreatine (PCr), creatine (Cr), γ-
aminobutyric acid (GABA), glutamine (Gln), gluta-
m a t e ( G l u ) , p h o s p h o r y l c h o l i n e ( P C h o ) ,
glycerophosphorylcholine (GPC), gluthathione (GSH),
glucose (Glc), lactate (Lac), glycine (Gly), myo-inositol
(mIns ) , N-ace ty l a spa r t y lg lu t ama t e (NAA) , N-
acetylaspartylglutamate (NAAG), ascorbate (Asc),
phosphoryl-ethanolamine (PE), scylloinositol (Scyllo),
taurine (Tau), and an experimentally measured macromol-
ecule baseline. Unsuppressed water 1H MR spectra were
used as an internal reference for the absolute quantifica-
tion of metabolite concentrations. Tissue composition in-
side the MRS volume used for water content calculation
and partial volume correction was calculated based on the
segmentation of magnetization-prepared rapid gradient-
echo (MPRAGE) (Mugler and Brookeman 1990) images
(TE/TR = 2.98/2300 ms, TI = 900 ms, flip angle = 9
degree, FOV = 240 × 256 mm2, matrix = 240 × 256, slice
thickness = 1.2 mm) MPRAGE images using an in-house
software (more details are reported elsewhere, Xin et al.
2016).
Statistical analysis
Statistical analyses were performed with SPSS (SPSS,
Chicago, Illinois). Differences between groups in socio-
demographics and clinical characteristics were assessed with
Chi-square or T test as appropriate. To investigate the effect of
cannabis on prefrontal Glu levels, an univariate analyses of
covariance (ANCOVAs) was used, with mean [GlumPFC] en-
tered as dependent variable, group as fixed factor (EP-users;
EP non-users and HC); age and gender as covariates of no
interest. To examine the effect of cannabis across the users’
sample, the same analyses were performed with frequency of
use (never or occasional vs. daily), and age at first use (< or
> 15 years) separately entered as fixed factors. The same anal-
yses were repeated entering alcohol use, number of cigarettes
smoked and medication (CPZ equivalents) as nuisance vari-
ables. Analyses performed for Gln, NAA and GABA are
shown in Supplementary materials.
Differences in neuropsychological measures between EP-
users, non-users, and controls were investigated using a mul-
tivariate analysis of covariance (MANCOVA).
Finally, correlations between mean GlumPFC values
and cognitive measures were tested with Pearson’s cor-
relation coefficient. The correlation analyses were per-
formed only on neuropsychological domain that differ-
entiate within patients depending on their cannabis us-
age. A Fisher r-to-z transformation of the correlation
coefficients was used to compare the strength of the
correlations between groups. (Calculation for the test
of the difference between 2 independent correlation co-
efficients is available from http://quantpsy.org).
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Fig . 1 A 1H MR spec t rum of media l pre f ron ta l cor tex
(VOI = 20 × 20 × 25 mm3) shown in the transverse slice of T1-
weighted MPRAGE images) acquired with the SPECIAL sequence at
3 T (TE/TR = 6/4000 ms, number of averages = 148), the corresponding
LCModel spectral fit, fit residual and Glu fit
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Results
Socio-demographic characteristics
There were no significant differences in age, gender, and
handedness between EP subjects and HC, indicating that
patients and controls were well matched for these factors.
As expected, patients had a lower level of education than
controls (t = 4.88, p = 0.001). PANSS was similar for the
two groups, with EP users having 62.7(17.7) and EP non-
users 64.1(15.8) mean total PANSS score [t = −.26
p = 0.7]. At 36 months follow-up within the users, 11
patients were diagnosed with schizophrenia, 4 with brief
psychotic disorder, 3 with schizoaffective disorder.
Among the non-users group, 9 patients were diagnosed
with schizophrenia, 4 with schizoaffective disorder; 2
with bipolar disorder and another 2 with brief psychotic
disorder. Main clinical characteristics are presented in
Table 1.
Cannabis and patterns of use
51.4% (N = 18) of patients were currently cannabis
users, 10 among them were occasional users (used week-
ly or less), and another 8 were daily users (daily usage or
more than 3 times per week). The mean age at onset of
cannabis use were 17 ± 4.5 years, with cannabis users
being more likely alcohol users [χ2(4,5), p = 0.02] and
cigarettes smokers [(χ2(18,2), p < 0.001]) compared to
non-users. There were no statistical differences in age,
gender, medication (Cpz equivalents) and duration of ill-
ness between the two groups (users Vs non-users). EP
users had a lower level of education than non-users
(t = 3.82, p = 0.001). Other drugs (cocaine, stimulants,
heroine, and opioids) were minimally used, with 1 EP
users having a concomitant, sporadic use of cocaine.
Within the EP non-users group there was only 1 subject
who had used cannabis in the past, occasionally and
during 3 years, but who had stopped smoking two years
before entering the study.
Neuropsychological performance
Complete neuropsychological performances are detailed
in Table 2. As expected, neuropsychological performances
were deeply affected in patients as compared to healthy
controls particularly when considering EP users, while a
less cognitive impairment was observed in EP non-users
F(2.57)=; p < 0.001; d = 0.51. Working memory was the
only domain found to be impaired in EP users compared
to their non-using counterpart, and that entered the subse-
quent correlative analyses. Patterns of cannabis use were
not significantly related to any cognitive measures; age at
which regular cannabis use commenced did not have a
significant effect either.
[GLUmPFC] and cannabis use
[GlumPFC] was measured by short-TE
1H MRS at 3T and
quantified using LCModel with CRLBs of 2.0 ± 0.5%
(mean ± SDMean). [GlumPFC] levels in EP users were signif-
icantly lower (12.7 ± 1.3 μmol/g) than in both EP non-users
(13.9 ± 1.5 μmol/g) and HC (14.2 ± 0.9 μmol/g),
[F(4.66) = 7.1; p = 0.002] with a medium effect size of
d = 0.4. Bonferroni post-hoc tests showed a significant reduc-
tion on [GlumPFC] levels between EP-users and healthy con-
trols (p = 0.001) and also between EP users and EP non-users
(p = 0.013); while controls and EP non-users did not differ
(p = 0.9).
When alcohol and cigarette intake, as well as medication
(CPz equivalents) was set as nuisance factors in the model, all
results retain their statistical significance.
Patterns of use did not significantly affect [GlumPFC] levels
[F(4,16) = 0,1; p = 0.7], albeit every day users having a slight-
ly lower mean [GlumPFC] levels (12.5 ± 1.3 μmol/g) than
occasional users (13.2 ± 0.9 μmol/g), respectively. Finally,
we evaluated the effect of age at first use, and found no sig-
nificant differences in mean [GlumPFC] levels between early
(< 15 years) and late onset cannabis users (> 15 years) (Fig. 2).
Correlation between [GLUmPFC] and clinical
characteristics
[GLUmPFC] levels were not related to mean duration of illness
(r = − 11, p = 0.3), and neither to PANSS total scores
(r = − 0.4; p = 0.4). CPZ equivalents displayed a significant
positive association with [GLUmPFC] (r = .34; p = 0.03).
Correlation between [GLUmPFC] and working memory
In the sample as a whole (both EP and controls), mean
[GLUmPFC] levels positively correlate with working mem-
ory (WM) (r = .37, p = 0.002). When running correlations
separately for each group, this correlation still remains
significant in controls (r = .43; p = 0.01) but not in EP
non-users or EP users. After controlling for age and years
of education, results maintain significance. EP users and
controls demonstrate, at trend level, differences in corre-
lation coefficients of [GLUmPFC] with WM (z = 1.4,
p = 0.07) (Fig. 3).
Correlations between mean GlumPFC and age
Age was significantly negatively associated with mean
[GlumPFC] levels in the combined sample (r = −.30;
p = 0.006) and independently in EP (r = − .36; p = 0.02).
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Within patients, the [GlumPFC]-decline with age was found in
EP users (r = − .46; p = 0.04) but not in EP non-users. In EP
users, these results remain significant when controlling for
Cpz equivalents (Fig. 4).
Discussion
To the best of our knowledge, this is the first study investigat-
ing the effect of cannabis use at neurochemical level in a
representative sample of EP patients, comparing their non-
users counterpart and normative control population. Our main
finding, which is in line with our principal hypothesis, is that
cannabis use is significantly associated with decreased pre-
frontal Glu levels. Additional analyses also revealed that
working memory performance was impaired in cannabis users
as compared to non-users. Furthermore, our results go further
and suggest that cannabis is implicated in the stronger Glu-
decline with age, with some relevance for the progression of
the disease.
Fig. 2 [GlumPFC] was lower in
EP users comparing to both HC
and EP non-users, while no
differences were observed
between EP non-users and con-
trols. From left to right [GlumPFC]
in healthy controls, EP non-users
and EP users, respectively. Each
horizontal bar indicates the mean
value of the group. **P = .001;
*P = .01
Table 2 Neuropsychological performance in EP cannabis users, non-users, and healthy controls
Cognitive domain
• subtests
Mean (SD) Pa value
EP usersb
(N = 18)
EP non-usersc
(N = 17)
HCd (N = 33) Effect size
(Cohen’s d)
EP users Vs EP
non-users
EP users
Vs HC
EP non-users
Vs HC
Speed of processing 34.3 (14.7) 44.2 (11.7) 54.3 (5.8) 0.42 .05 .001 .02
• TM- A 35.9 (14) 45 (9.8) 50 (13.2) 0.21 .20 .002 .79
• Symbol coding
(BACS)
33.1 (13.3) 42.7 (10.6) 45.8 (14.2) 0.16 .18 .01 .92
• Verbal fluency 44.4 (13.4) 49.1 (13.5) 56.8 (11.4) 0.17 .98 .006 .23
Sustained attention
• CPT 37.9 (11.7) 41.4 (11.7) 52.5 (8.5) 0.31 .24 .001 .007
Working Memory 41.2 (12.7) 49.2 (6.6) 56.8 (7.5) 0.36 .07 .001 .06
• LNS 41 (11.4) 50.2 (8.1) 54.5 (6.5) 0.33 .02 .001 .41
• Spatial span (WMS) 44.4 (12.1) 48.5 (6.9) 57.3 (9.2) 0.27 .82 .001 .03
Problem Solving
• Mazes-NAB † 43 (12.6) 40.9 (11.5) 56.6 (7.9) 0.34 .85 .002 .001
Verbal Learning
• Hopkins VLT-revised 38.3 (13.7) 46.7 (19.4) 57.1 (11.3) 0.26 .35 .001 .11
Visual Learning
• BVMT-revised 45 (13.8) 51.2 (8.4) 55.2 (6.9) 0.17 .24 .07 .53
TM-A trail-making test A, CPT continuous performance test-identical pairs, LNS letter-number span, NAB neuropsychological assessment battery, VLT
verbal learning test, BVMT brief visuospatial memory test
aP values are corrected for Bonferroni group comparisons
bMissing data for 4 subjects
cMissing data for 4 subjects
dMissing data for 1 subject
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[GlumPFC] in EP cannabis-users, non-users and healthy
subjects
Our finding of reduced [GlumPFC] levels in EP users is con-
sistent with the decreased Glu/Glx metabolite levels previous-
ly reported in the anterior cingulated-cortex (Muetzel et al.
2013; Prescot et al. 2013) and in basal ganglia (Chang et al.
2006; Prescot et al. 2011) of adolescent cannabis users. So far,
only one study has been conducted in a cohort of early phase
schizophrenia patients, reporting decreased frontal Glx levels
in currently or past multi-substances users (Bernier et al.
2016). Making comparisons across studies is difficult: firstly,
the outcome measure vary between studies, involving Glx
metabolite measurement for two studies (Muetzel et al.
2013; Bernier et al. 2016) and Glu metabolite measurement
for the others (Chang et al. 2006; Prescot et al. 2011, 2013).
Secondly, the reference for quantification of Glu levels is dif-
ferent across studies; some studies using water (Prescot et al.
2011, 2013), while others use cerebrospinal fluid, total crea-
tine, or phosphocreatine + creatine (Chang et al. 2006;
Muetzel et al. 2013).
Discussing our findings is also complicated due to the lack
of exhaustive evidence in the field. So far, only a few studies
have focused on Glu-abnormalities in the frontal region before
the full blown onset of the disorder (Treen et al. 2016), in EP
and established schizophrenia; with some evidence that gluta-
matergic variations might be sensitive to illness stage (Merritt
et al. 2016). It is well known, that the severity of symptoms
associated with psychotic disorders typically evolves over
time. Before the onset of a frank psychosis, subjects often
present attenuated psychotic symptoms, usually showing a
marked decline in social and occupational functioning, a clin-
ical state referred to as Ultra High Risk (UHR) for psychotic
disorder (Yung et al. 2005). Starting from this prodromal
phase, progressive changes in brain volume, including the
PFC, and disturbances in Glu-neurotransmission (Marsman
et al. 2013) may occur. Tibbo et al. (2004) found significantly
higher levels of Glu in the right medial frontal lobe of HR
compared to controls, although other studies failed to replicate
these findings. Purdon et al. (2008) finding the absence of
differences in Glu metabolites levels between HR and HC in
the same brain region, as was for Yoo et al. (2009).
Concordantly, analyzing the medial-PFC in HR subjects, EP
and schizophrenia patients, Natsubori et al. (2014) revealed
significant decrease in Glu metabolites only in the schizophre-
nia group.
The decreased prefrontal Glu levels observed in EP users
may be cautiously interpreted as the result of the interaction
between cannabis usage and psychosis rather than the effect of
illness itself, as no differences were detected between non-
users patients compared to controls. Moreover, the findings
of a lack of Glu abnormalities in EP non-users may be ex-
plained in the light of those studies that did not show Glu-
levels decrease in the prefrontal region of EP patients, but
consistently report such abnormalities in chronicity, as sug-
gesting a role for cannabis use in driving the earlier onset of
frontal Glu abnormalities. This needs however to be
established in the context of a longitudinal study.
a b c
Fig. 3 [GLUmPFC] levels and workingmemory (WM)were significantly positive correlated in a healthy controls (r = .43, p = .01). EP users and controls
demonstrated a trend in differences in correlation coefficients of [GLUmPFC] with WM, (z = 1.4, p = 0.07).
b ca
Fig. 4 [GLUmPFC] levels and age were: negatively correlated in c EP users (r = − .46, p = .04), not significantly related in b EP non-users and a healthy
controls
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[GlumPFC], age and cognition
The decrease of [GlumPFC] in our EP-users is intriguing and
may be related to the behavioral changes observed in cannabis
users. The glutamatergic system plays an important role in
age-related cognitive decline and cognitive disorders, as tight
regulation of Glu is essential for normal cognitive function
(Rubino et al. 2015). In particular, glutamatergic transmission,
that controls recurrent excitation within PFC networks, is a
crucial modulator for working memory (WM) (Goldman-
Rakic 1995), by supporting retention of spatial information
during the delay period of WM tasks (Deco and Rolls 2003).
Exogenous THC exposure induces spatial WM deficits,
throughout a modulation of Glu release, whose molecular un-
derpinnings could be the establishment of less synaptic con-
tacts and/or less efficient synaptic connections, in those brain
regions like PFC that have high density of CB1 receptors
(Rubino et al. 2009). These abnormalities may be reflected
at neurochemical level by the reduction of Glu concentration
seen in our EP users. Consistently with these observations,
LNS (Letter Number Span), a putative executive function
working memory test requiring among others attention and
temporary storage of information capacities (Twamley et al.
2006), was the only neuropsychological test, albeit the limita-
tion of the small sample size, which was impaired in EP users
compared to non-users, and displayed a disrupted correlation
to Glu concentration in cannabis users. Based on this back-
ground, the lack of a significant correlation between Glu
levels and WM performance, observed in EP users, might
probably stands for an alteration in WM signaling pathways,
mediated by the reduced frontal glutamatergic tone related to
cannabis use.
Counterintuitively, prior studies in EP demonstrated that
subjects who used cannabis (especially those who used prior
to age 16) performed better than non-using on global cogni-
tive functioning, including WM. Moreover, these studies ev-
idenced that the cognitive profile depends on the age at which
regular cannabis use begins, and that comorbid cannabis use is
associated with a superior cognitive profile only in
schizophrenia-spectrum disorders but not in bipolar psychosis
(Hanna et al. 2016). We failed to replicate these observations,
EP users displayed poorer performances in all neuropsycho-
logical domains explored, compared both to EP non-users and
HC. In addition, age at which cannabis use started was not
related to cognitive performances either. Probably this could
be explained by the fact that our patients were late onset users,
starting cannabis consuming on average at age 17, and hetero-
geneous in terms of diagnosis.
Current evidence has shown that Glu have also consider-
able potential as biomarker of disease progression (Brandt
et al. 2016), although the implications of changes in Glu on
neuronal function are still not clear (Wijtenburg et al. 2015).
Given the tight metabolic relationship between glutamate and
both NAA and Gln, changes in Glu levels that are not accom-
panied by NAA or Gln changes are surprising. NAA is an
intermediate metabolite serving as a reservoir for replenishing
Glu when necessary (Clark et al. 2006). Similarly, Glu and
Gln are metabolically coupled, as Glu is released into the
synaptic cleft and rapidly transported into astroglia where it
is enzymatically converted into Gln. Subsequently, Gln is
shuttled back into neurons for conversion to Glu. Our finding
of a diminished glutamatergic tone and of a greater Glu-
decline with age in EP users, without significant related
changes in NAA or Gln (Supplementary material), is only
partially in line with the results of the only existing study
investigating Glu-metabolites in schizophrenia patients users
(Bernier et al. 2016). The authors found a reduction in Glx and
mIns levels related to cannabis, alcohol, and methamphet-
amine use but failed to include patients without a lifetime
history of substance use (non-users). Differences in both con-
suming behaviors (polysubstance vs cannabis use) and dura-
tion of illness between the studies may have probably
accounted for these discrepancies.
Strengths and limitations
This study has a number of strengths. We have evaluated the
role of cannabis in relation to brain neurochemical properties
for the first time in a representative EP sample. The impact of
cannabis substance used was studied independently of other
substances. In addition, considering all our patients were in
the early phase of psychosis, cannabis use had occurred prior
to (or around) illness onset and not as a consequence of the
illness. Also, patients were not exposed to long-term pharma-
cological treatment, making it unlikely that Glu alterations
were due to antipsychotic medications. Moreover, when co-
varying for mean antipsychotic dosage, all our results retain
their significance.
Several limitations must be noted. First of all, this study
did not include a group of controls with a lifetime history of
cannabis use, the real clinical-setting nature of the study
might account for this. Moreover, the cross-sectional de-
sign, does not allow for a strong cause-effect interpretation
of the findings. Furthermore, although other studies that
have used self-report measures have also shown an associ-
ation with brain structural alterations (Rigucci et al. 2016),
the lack of objective measures of cannabis use in our study
is an important limitation. However, there is published ev-
idence indicating that asking patients with psychosis about
their use of cannabis is, at least in some situations, more
accurate than, or as reliable as, urine or blood testing which
can only provide information on recent use (Freeman et al.
2014). The lack of a measure of the potency of cannabinoid
compounds might nevertheless also affect the robustness of
our findings; indeed, the recent changes in the composition
of Bstreet^ cannabis have created a new and complex
20 Psychopharmacology (2018) 235:13–22
landscape for the understanding the neurobiological impact
of cannabis products. In line with the new tendencies in
Europe, Switzerland cannabis drug market has recently
changed, with an increased mean THC content both in resin
and herbal strains (Data from the addiction monitoring in
Switzerland, 2015, http://www.suchtmonitoring.ch). Future
studies evaluating the effects of cannabis use on brain
structure and function should therefore include a careful
assessment of cannabis potency. Differences in paradigms
used in MRS, such as magnetic field strength, may
influence results and need to be considered when
comparing results between studies. Separating glutamate
and glutamine at lower field strengths being challenging,
despite promising new approaches (Zhang and Shen 2016)
, and despite studies at 7 T, having shown improved preci-
sion of glutamate measurement (Mekle et al. 2009) com-
pared to lower field strengths, replication of these findings
with an enhanced spectral sensitivity and resolution is
needed.
In summary, our research which focused on prefrontal re-
gion revealed that cannabis use in the early phase of psychosis
is associated with decreased Glu levels in the PFC and with a
stronger Glu-decline with age, without significant changes in
NAA or Gln. Our results suggest that cannabis might acceler-
ate the progression of psychosis, which is seen at neurochem-
ical levels with prefrontal Glu-abnormalities in EP users that
normally are not found in the early stage of the illness.
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